Search

Paul W Erhardt

from Sylvania, OH
Age ~77
Get Report
Also known as:
Paul Dr Erhardt
Phone and address:
5036 Fairway Ln, Sylvania, OH 43560
(419) 882-8681
Related to:
Theresa J Haskins, 64Christine M Ludlum, 61Judith M Erhardt, 76Carl O OwedChristine G Erhardt, 48William J Erhardt, 53Michael P Erhardt, 51
Connected to:
Ann K Erhardt, 55Bonnie L Erhardt, 67Christopher Erhardt, 49Dawn Erhardt, 57Drew D Erhardt, 62Erica R Erhardt, 46Gloria C Erhardt, 70Greta M Erhardt, 57Jesse N Erhardt, 43Linda F Erhardt, 77

Paul Erhardt Phones & Addresses

  • 5036 Fairway Ln, Sylvania, OH 43560 (419) 882-8681 (419) 882-5725
  • Toledo, OH
  • Zanesfield, OH
  • Jerome, MI
  • Long Valley, NJ
  • Lucas, OH
  • Idaho Falls, ID
  • 5036 Fairway Ln, Sylvania, OH 43560 (513) 751-8979

Public records

Vehicle Records

Paul Erhardt

View page
Address:
5036 Fairway Ln, Sylvania, OH 43560
Phone:
(419) 882-8681
VIN:
3G5DA03L67S526549
Make:
BUICK
Model:
RENDEZVOUS
Year:
2007

Business Records

Name / Title
Company / Classification
Phones & Addresses
Paul Erhardt
Director, President
Wci Realty, Inc
Paul Erhardt
Director, Vice President
Pelican Landing Golf Resort Ventures, Inc
Paul Erhardt
Director, Secretary, Vice President
Carrara at Talis Park Condominium Owners' Association, Inc
Paul Erhardt
Secretary, Vice President
Wci Communities Management, LLC
Paul Erhardt
Secretary, Vice President
Wci Communities, LLC
Investors, Nec
Paul Erhardt
Secretary
Wci Communities, Inc
Operative Builders Real Estate Agent/Manager · Real Estate Agent
(239) 947-2600, (954) 575-4200

Publications

Us Patents

Aralkyl Ester Soft Drugs

View page
US Patent:
6750238, Jun 15, 2004
Filed:
May 12, 2000
Appl. No.:
09/570485
Inventors:
Paul W. Erhardt - Sylvania OH
Assignee:
The University of Toledo - Toledo OH
International Classification:
A61K 31415
US Classification:
514401, 5483331
Abstract:
The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered. The parent drug compound is modified by forming one or more of a predetermined chemical arrangement within the parent drug structure where the chemical arrangement is AâÃâ(R)âXâRâ; where A is absent or is a tether moiety which allows for a metabolically stable chemical connection to be made to the parent drug compound; à is a substituted aryl or heteroaryl system that is already present within the parent drug compound or is specifically added to the parent drug compound via A; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is either also already present within the parent drug compound or is specifically added to the parent drug compound via connection to Ã; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via connection to R; and, Râ is an added alkyl, alkenyl, or aralkyl group either branched or unbranched containing from 1 to 10 carbons, other common leaving group, or a structural element already present as an inherent portion of the parent drug compound.

Method And Compositions For Treating Persistent Pulmonary Hypertension Using Aralkyl Ester Soft Drugs

View page
US Patent:
6756047, Jun 29, 2004
Filed:
Nov 18, 2002
Appl. No.:
10/299044
Inventors:
Paul W. Erhardt - Sylvania OH
Moustafa M. Aouthmany - Sylvania OH
Assignee:
The University of Toledo - Toledo OH
International Classification:
A61F 1300
US Classification:
424422
Abstract:
A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious parent drug compound so as to retain efficacy while re-directing a preferred route and rate of the parent drug compounds metabolism to an inactive or very weakly active and non-toxic metabolite are disclosed. The chemical arrangement is wherein is a phenyl, substituted aryl or heteroaryl system that is already present in the parent drug compound or is specifically added to the parent drug compound via a metabolically stable connection; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is already present in the parent drug compound or is added to the parent drug compound via a metabolically stable connection to ; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via a metabolically stable connection to R; and, Râ is an added alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons, or is a structural element already present as an inherent portion of the parent drug compound.

Method For The Selective Removal Of Acyl-Functionality Attached To The 2'-Hydroxy-Group Of Paclitaxel-Related Derivatives

View page
US Patent:
6846937, Jan 25, 2005
Filed:
Sep 27, 2002
Appl. No.:
10/491576
Inventors:
Paul W. Erhardt - Sylvania OH, US
Wieslaw A. Klis - Toledo OH, US
Jeffery G. Sarver - Rossford OH, US
Assignee:
The University of Toledo - Toledo OH
International Classification:
C07D30514
US Classification:
549510, 549511
Abstract:
A method for removing acyl-groups appended by an ester linkage to the 2′-hydroxyl group present in paclitaxel-related molecules comprising treatment with alcohol under non-acidic conditions. 2′,7-bis-Monochloroacetylpaclitaxel analogs are converted to their corresponding 7-monochloroacetyl derivatives by treatment with alcohol under non-acidic conditions.

Method And Compositions For Temporarily Incapacitating Subjects

View page
US Patent:
7049326, May 23, 2006
Filed:
Nov 18, 2002
Appl. No.:
10/299027
Inventors:
Paul W. Erhardt - Sylvania OH, US
Assignee:
The University of Toledo - Toledo OH
International Classification:
A61K 31/445
C07D 211/06
US Classification:
514329, 546224
Abstract:
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds are rapidly metabolized to inactive and non-toxic metabolites when exposure to the modified compounds is halted. One or more of a predetermined chemical arrangement is incorporated into the parent compound having the formula: φ-R—X—R′; where φ is a phenyl, substituted aryl or heteroaryl system present in the parent compound or is added to the parent compound; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons present in the parent compound or is added to φ; X is a carboxyl, sulfoxyl or phosphatyl function added to R; and, R′ is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons is added to X in a metabolically labile manner, or is a structural element already present as an inherent portion of the parent compound that is connected to X in a metabolically labile manner.

Aralkyl Ester Soft Drugs

View page
US Patent:
7164027, Jan 16, 2007
Filed:
May 28, 2004
Appl. No.:
10/857683
Inventors:
Paul W. Erhardt - Sylvania OH, US
Assignee:
The University of Toledo - Toledo OH
International Classification:
C07D 233/78
US Classification:
5483211
Abstract:
The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered. The parent drug compound is modified by forming one or more of a predetermined chemical arrangement within the parent drug structure where the chemical arrangement is A-Ø-(R)—X—R′; where A is absent or is a tether moiety which allows for a metabolically stable chemical connection to be made to the parent drug compound; Ø is a substituted aryl or heteroaryl system that is already present within the parent drug compound or is specifically added to the parent drug compound via A; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is either also already present within the parent drug compound or is specifically added to the parent drug compound via connection to Ø; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via connection to R; and, R′ is an added alkyl, alkenyl, or aralkyl group either branched or unbranched containing from 1 to 10 carbons, other common leaving group, or a structural element already present as an inherent portion of the parent drug compound.

Methods For Synthesizing Glycinols, Glyceollins I And Ii And Isoflavenes And Chromanes Using A Wittig Reaction, And Compositions Made Therewith

View page
US Patent:
8507549, Aug 13, 2013
Filed:
Jan 9, 2012
Appl. No.:
13/346059
Inventors:
Paul W. Erhardt - Sylvania OH, US
Rahul S. Khupse - Toledo OH, US
Amarjit Luniwal - Toledo OH, US
Assignee:
The University of Toledo - Toledo OH
International Classification:
A61K 31/353
C07D 493/04
C07D 493/14
C07D 311/58
US Classification:
514456, 549406, 549383, 549382
Abstract:
Methods for synthesizing glycinols, glyceollins I and II, and isoflavene and chromane compounds using a Wittig reaction, compositions made therewith, and uses thereof are described.

Methods For Synthesizing Glycinols, Glyceollins I And Ii, Compositions Of Selected Intermediates, And Therapeutic Uses Thereof

View page
US Patent:
8563599, Oct 22, 2013
Filed:
Mar 3, 2009
Appl. No.:
12/921013
Inventors:
Paul W. Erhardt - Toledo OH, US
Rahul Khupse - Toledo OH, US
Jefferey G. Sarver - Toledo OH, US
Thomas E. Cleveland - New Orleans LA, US
Stephen M. Boue - New Orleans LA, US
Thomas E. Wiese - New Orleans LA, US
Matthew E. Burow - New Orleans LA, US
John A. McLachlan - New Orleans LA, US
Assignee:
The United States of America, represented by the Secretary of Agriculture - Washington DC
Xavier University of Louisiana - New Orleans LA
University of Toledo - Toledo OH
International Classification:
A61K 31/352
US Classification:
514453
Abstract:
Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.

Aralkyl Ester Soft Drugs

View page
US Patent:
20030096858, May 22, 2003
Filed:
Nov 18, 2002
Appl. No.:
10/298879
Inventors:
Paul Erhardt - Sylvania OH, US
International Classification:
A61K031/4025
A61K031/235
C 07D 4 1/02
US Classification:
514/422000, 514/533000, 548/518000, 560/037000
Abstract:
The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered. The parent drug compound is modified by forming one or more of a predetermined chemical arrangement within the parent drug structure where the chemical arrangement is A--Ø--(R)—X—R′; where A is absent or is a tether moiety which allows for a metabolically stable chemical connection to be made to the parent drug compound; Ø is a substituted aryl or heteroaryl system that is already present within the parent drug compound or is specifically added to the parent drug compound via A; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is either also already present within the parent drug compound or is specifically added to the parent drug compound via connection to Ø; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via connection to R; and, R′ is an added alkyl, alkenyl, or aralkyl group either branched or unbranched containing from 1 to 10 carbons, other common leaving group, or a structural element already present as an inherent portion of the parent drug compound.
Control profile
Paul W Erhardt from Sylvania, OH, age ~77 Get Report